AVITHRAPID

European Researchers' Night at Frascati Scienza - AVITHRAPID project Frascati Scienza celebrated 20 years of science, passion, and curiosity with the 2025 edition of the European Researchers’ Night. The event filled squares, schools, museums, and institutions throughout Italy with a week packed with events dedicated to scientific dissemination: a journey through STEAM – Science, Technology, Engineering, Art, and Mathematics – culminating on September 26, 2025, with the European Researchers’ Night. The European Researchers’ Night was the opportunity to introduce the AVITHRAPID project to the research community and the general public. It brought its results to researchers closer to the public, attracting over 30.000 visitors to all events, while increasing the interest of young people in science and research careers and showing how researchers’ work affects our daily lives. Francesca Ceccherini Silberstein with her team from University of Rome Tor Vergata distributed and illustrated some dissemination material prepared for this specific event. Poster

avithrapid.eu/europe...

At the end of September, Frascati Scienza celebrated 20 years of science during the European Researchers’ Night 2025 🇪🇺
Through Tor Vergata University, AVITHRAPID engaged with the public, sharing advances in antiviral research.
#AVITHRAPID #ERN2025 #ScienceOutreach

20th October AVITHRAPID hosted a seminar with the APPEAL project, fostering an inspiring exchange of ideas within the #HorizonEU framework.

Today is Global Handwashing Day.

Hand hygiene prevents infections, yet the development of antivirals and small molecules is essential to tackle emerging viruses and safeguard public health.
#GlobalHandwashingDay #HealthInnovation #DrugDiscovery #Science

Small molecules are key to the future of antivirals: fast to develop, easy to deliver, globally accessible.

At AVITHRAPID, we put them at the core of our mission to protect against emerging viruses.

#AVITHRAPID #Antivirals #DrugDiscovery

💊 Small molecules = game-changer for antivirals.

Where is their biggest impact?
- Emerging viral threats
- Resistant strains
- Global access
- Other / not sure

Vote & share your view in the comments!

#AVITHRAPID #Antivirals #DrugDiscovery #Biotech

AVITHRAPID will be at the European Researchers’ Night on 26 Sept in Italy 🇮🇹.
Our scientists will share how small molecules and advanced research shape the future of antivirals.
#AVITHRAPID #ERN2025 #Innovation

AVITHRAPID will be part of Settimana della Scienza in Italy (20–27 Sept) 🇮🇹 through our partner Tor Vergata University.
At their stand, you can learn more about our mission and the future of antiviral drug discovery.

Program: www.frascatiscienza....

#AVITHRAPID #ScienceWeek #ERN2025

AI is changing healthcare 🚀

But when it comes to drug discovery, which impact do you see first?
- Speed of development
- Personalized therapies
- Cost savings
- Still unclear

Cast your vote ⬇️

#AVITHRAPID #Innovation #DrugDiscovery

Our recent poll sparked a key conversation:
🧬 Vaccines prevent
💊 Antivirals treat
Both are essential pillars of #globalhealth.
At #AVITHRAPID, we’re working to accelerate antiviral research - ensuring faster, safer, and smarter therapies that complement vaccines.

🧪 Vaccines prevent. Antivirals treat.
Both are vital — but which will shape the future of infectious disease? 🦠
Vaccines
Antivirals
Both equally
Not sure
👉 Vote in the poll and share your thoughts in the comments!
Your perspective matters for the future of global health.

AVITHRAPID and Area Science Park Join Forces to Drive Antiviral Innovation - AVITHRAPID project AVITHRAPID has signed a new Memorandum of Understanding (MoU) with Area Science Park, a leading Italian research hub, to accelerate innovation in antiviral therapeutics and preventive strategies. This agreement marks a significant step forward in strengthening Europe’s ability to anticipate, prevent, and respond to future infectious disease threats. At its core lies a shared ambition: […]

AVITHRAPID and Area Science Park just published an annoucement about their new partnership to drive antiviral and preventive innovation.
The MoU strengthens Europe’s scientific response to future health threats.
📰 Read more: avithrapid.eu/avithr...
#AVITHRAPID #ScienceFeed #PublicHealth #Innovation

AVITHRAPID is advancing broad-spectrum antivirals across Europe — and we’re sharing it with you.

Subscribe to our newsletter for updates on research, events, partnerships & more.
📩 avithrapid.eu/newsle...
#AVITHRAPID #ScienceFeed #PublicHealth

Broad-spectrum antivirals (BSAs) target host or conserved viral parts, working across virus families. They deploy fast and aid pandemic prep without needing virus ID. Trade-offs: toxicity, resistance risk, less precision. Still, BSAs could be key for unpredictable outbreaks. #HealthTech #Science

It’s #WorldBreastfeedingWeek - a reminder that science must reflect everyone’s needs.
At #AVITHRAPID, we believe preparedness means inclusion, equity and long-term impact.
#ScienceFeed #HealthEquity

Who’s behind AVITHRAPID?
A Europe-wide network of labs, hospitals, and research centres working together on broad-spectrum antivirals.

From hepatitis C to tomorrow’s viruses: AVITHRAPID builds on proven science to prepare for future outbreaks.

#WorldHepatitisDay #ScienceFeed

AVITHRAPID has signed an MoU with @AREASciencePark to strengthen Europe’s preparedness for future pandemics.
The partnership will boost rapid antiviral development, training, funding strategy & long-term impact.

#AVITHRAPID #ScienceFeed #PandemicResponse

What’s next for AVITHRAPID?
Following our meeting in Berlin , we’re entering a critical phase — improving existing antivirals while evaluating new broad-spectrum compounds.
Stronger preparedness through innovation.

#AVITHRAPID #PandemicPreparedness #OneHealth

🧪 Last 16-17 June, the #AVITHRAPID team met in Berlin to plan next steps in antiviral preparedness! Great science, strong collaboration — and a few laughs too 😄
📸 Highlights below!
#HorizonEU #DrugRepurposing #PandemicPreparedness

🧪 Last 16-17 June, the #AVITHRAPID team met in Berlin to plan next steps in antiviral preparedness! Great science, strong collaboration — and a few laughs too 😄
📸 Highlights below!
#HorizonEU #DrugRepurposing #PandemicPreparedness

Neglected tropical diseases (NTDs) affect over 1.5 billion people worldwide, yet treatment options remain limited. Broad-spectrum antivirals offer a promising solution. Let’s push for innovation and progress. Stay informed on the latest updates—subscribe to our newsletter at www.avithrapid.eu

Our consortium partners are meeting next week in Berlin for an exciting session to exchange ideas, review progress, and plan upcoming work. Are you part of a team focused on antiviral development? Reach out to explore future collaborations with us! #AVITHRAPID #Collaboration #Innovation

Market gaps in broad-spectrum #antivirals are clear: limited #discovery platforms, resistance concerns, clinical trial barriers, and access issues. It’s time to bridge these gaps and innovate to protect global health. Subscribe to our newsletter: www.avithrapid.eu

The world isn’t short on brilliant science.
It’s short on collaboration, clarity, and courage.

In the face of the next crisis, how we organize knowledge may matter more than how we generate it.

We can’t afford siloed thinking anymore.
#AVITHRAPID

Meet Paulo da Silva, R&D Specialist at @IT4Innovations 🇨🇿 & key partner in #AVITHRAPID. With HPC expertise, Paulo drives the in-silico engines accelerating antiviral discovery. 🧬💻

🎥 Watch the video & see how supercomputing helps fight pandemics!

#DrugDiscovery #HPC #PandemicPreparedness

Cys44 of SARS-CoV-2 3CLpro affects its catalytic activity SARS-CoV-2 encodes a 3C-like protease (3CLpro) that is essential for viral replication. This cysteine protease cleaves viral polyproteins to release f…

🔬 AVITHRAPID's Latest Discovery: Halicin Targets SARS-CoV-2 3CLpro. Our new study reveals that halicin binds to both Cys145 and Cys44 in 3CLpro, disrupting its function and stability. This dual targeting offers a promising avenue for broad-spectrum antiviral development www.sciencedirect.co...

AVITHRAPID was showcased at #AREVIR2025 in Cologne!
Francesca Incardona presented our mission to a hybrid audience of 120+ experts in infectious diseases, virology & AI.
Thanks to the organizers for the spotlight!
🌐 www.avithrapid.eu
#HorizonEU #OneHealth

🚨 Highlights from #AVITHRAPID at #INFACT2025 (Naples, April 3–5)!
Harnessing Computational Power – Presented by Carmine Talarico
💻 AVITHRAPID’s in silico pipeline for antiviral targets
🧬 Applied to Dengue virus
🔍 Public workflows, docking & MD-ready models
📂 Fully open-access

🚨 Highlights from #AVITHRAPID at #INFACT2025 (Naples, April 3–5)!
PLpro Inhibitors Poster – Presented by Antonietta Mollo
✔️ 7 validated molecular clusters
✔️ Hits in µM IC50 range
✔️ No toxicity, modest antiviral activity
✔️ X-ray co-crystallization & SAR studies ongoing

Meet the AVITHRAPID Consortium 🧪🔬

How are antiviral compounds screened and optimized? Francesca Esposito, Associate Professor at Università degli Studi di Cagliari, is developing biochemical assays to identify and refine antiviral inhibitors.

🎥 Watch the short video to learn more!